Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 71.4% during mid-day trading on Tuesday . The stock traded as high as C$0.12 and last traded at C$0.12. Approximately 592,088 shares were traded during mid-day trading, an increase of 516% from the average daily volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The firm has a market capitalization of C$9.15 million, a PE ratio of -5.25 and a beta of 0.20. The firm has a 50-day simple moving average of C$0.08 and a 200-day simple moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Health Care Stocks Explained: Why You Might Want to Invest
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Insider Trading – What You Need to Know
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
- What Are Earnings Reports?
- These 3 Retail Stocks Can Keep Winning in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
